We found that CD138+ cirMV counts were significantly higher in group 1 than in group 2 (p = 0.0138), and the ROC value for using CD138+ cirMV counts to diagnose RI in de novo patients with MM was 0.731 (Figure 6). This evidence concerns the gene SDC1 and Miyoshi myopathy.